Skip to main content
Premium Trial:

Request an Annual Quote

Life Tech's 3500 Sanger Sequencers Receive Regulatory Approval in Canada

NEW YORK (GenomeWeb News) – Health Canada has approved Life Technologies' 3500 series Sanger sequencers for diagnostic use, the firm announced today.

The company's Applied Biosystems 3500xL Dx Genetic Analyzer is an automated 24 capillary-based Sanger sequencer and its 3500 Dx is an eight capillary instrument.

The company received 510(k) clearance from the US Food and Drug Administration for the instruments along with its SeCore HLA typing kits in February.

"The current approval of the 3500 Dx Series Genetic Analyzers by Health Canada emphasizes Life Technologies' success in pursuing regulatory pathways for our diagnostics laboratory instruments, as well as our vision to becoming a global leader in the molecular diagnostics industry," Ronnie Andrews, president of medical sciences at Life Technologies, said in a statement.

Life Tech's 7500 Fast Dx and the QuantStudio Dx real-time PCR instruments are also approved for diagnostic use in Canada as Class I devices.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.